This clinical trial is focused on the long-term follow-up of individuals who have been treated with a medication called NTLA-2002. The study is specifically looking at people with a condition known as Hereditary Angioedema, which is a rare genetic disorder that causes sudden and severe swelling in different parts of the body. The treatment being studied, NTLA-2002, is a solution for infusion that contains messenger RNA, a type of genetic material, which is designed to target the kallikrein B1 gene (KLKB1). This gene is involved in the process that leads to the symptoms of Hereditary Angioedema.

The purpose of this study is to evaluate the long-term safety of NTLA-2002 in individuals who have previously received this treatment. Participants in the study will be monitored over an extended period to observe any potential side effects or adverse events related to the treatment. The study will also track the frequency of Hereditary Angioedema attacks and any changes in the use of medications needed to manage these attacks. Additionally, the study will assess changes in the overall quality of life for participants, using specific tools designed to measure this aspect.

Throughout the study, participants will attend regular visits to ensure their health and safety while collecting important data about the treatment’s effects. The study aims to provide valuable information about the long-term impact of NTLA-2002 on individuals with Hereditary Angioedema, contributing to a better understanding of how this treatment can be used effectively and safely in the future.